Citations with the tag: LEISHMANIASIS -- Treatment
Results 1 - 50
- Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate.
Thakur, C.P.; Kumar, K.; Sinha, P.K.; Mishra, B.N.; Pandey, A.K. // British Medical Journal (Clinical Research Edition); 10/10/1987, Vol. 295 Issue 6603, p886
Focuses on the treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate. Comparison between the cure rate of 20mg regimen and 10mg and 15mg regimens; Percentage relapse rate after the fourth course of treatment; Patients with nodular and erythematous disease and hypopigmented...
- Short-course multidrug treatment for visceral leishmaniasis in India.
Thakur, C.P.; Kumar, K.; Sinha, P.K.; Mishra, B.N.; Pandey, A.K. // Africa Health; May2011, Vol. 33 Issue 4, p64
The article reports on the randomized clinical trial which assesses the effectiveness of using the short-course multidrug treatment for visceral leishmaniasis in Bihar, India.
- Efficacy of miltefosine declined for visceral leishmaniasis in India.
Thakur, C.P.; Kumar, K.; Sinha, P.K.; Mishra, B.N.; Pandey, A.K. // Infectious Disease News; Sep2012, Vol. 25 Issue 9, p34
The article reports on the increase in the failure rate of miltefosine for the treatment of visceral leishmaniasis in India.
- American Cutaneous Leishmaniasis in U.S. Travelers.
Herwaldt, Barbara L.; Stokes, Susan L.; Juranek, Dennis D. // Annals of Internal Medicine; 5/15/93, Vol. 118 Issue 10, p779
Presents a study which characterized the exposures and practices of U.S. travelers who acquired cutaneous leishmaniasis in the Americas and highlighted problems they encountered in seeking medical care from U.S. physicians. Method of the study; Results and discussion; Conclusion.
Herwaldt, Barbara L.; Stokes, Susan L.; Juranek, Dennis D. // Africa Health; May2013, Vol. 35 Issue 4, p58
The article focuses on a study conducted on 375 patients suffering from Leishmaniasis which stated that topical treatment with paromomycin cream is effective.
Chance, M.L. // British Medical Journal (Clinical Research Edition); 11/7/1981, Vol. 283 Issue 6301, p1245
Focuses on the treatment and control of Leishmaniasis. Increase in the use of liposomes to encapsulate antileishmanial drugs; Availability of improved methods of isolation from animal tissue; Application of the techniques of biochemical taxonomy.
- Reply to Monge-Maillo et al.
Soto, Jaime; Berman, Jonathan // Clinical Infectious Diseases; Nov2013, Vol. 57 Issue 10, p1503
A response to the letter to the editor by the authors about their article "Concerns about topical treatment for New World cutaneous leishmaniasis" in the 2013 issue is presented.
- Combination therapy improves the treatment of visceral leishmaniasis.
Soto, Jaime; Berman, Jonathan // Clinical Infectious Diseases; 10/15/2008, Vol. 47 Issue 8, pi
The article discusses the study on combination therapy for treatment of visceral leishmaniasis within the issue.
- Correction: Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia.
Soto, Jaime; Berman, Jonathan // PLoS Neglected Tropical Diseases; Jun2014, Vol. 8 Issue 6, p1
A correction to the article "Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia" that was published in the 2014 issue is presented.
- Epidemic visceral leishmaniasis in southern Sudan...
Seaman, Jill; Mercer, Alec J. // Annals of Internal Medicine; 4/01/96, Vol. 124 Issue 7, p664
Focuses on epidemic, visceral leishmaniasis which is being experienced in southern Sudan. How visceral leishmaniasis syndrome is recognized; Number of countries reporting similar cases; What the disease is associated with; Study carried out on persons with the disease; Analysis of the findings;...
- Meglumine antimonate/miltefosine.
Seaman, Jill; Mercer, Alec J. // Reactions Weekly; 6/9/2012, Issue 1405, p24
The article describes the case of a 64-year-old woman who developed hypokalaemia and other toxicities while receiving meglumine antimonate, and subsequently miltefosine, for mucosal leishmaniasis, published in the March-April 2012 issue of the "Journal of Travel Medicine."
- Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral Agent.
Soto, J.; Toledo, J.; Gutierrez, P.; Nicholls, R. S.; Padilla, J.; Engel, J.; Fischer, C.; Voss, A.; Berman, J. // Clinical Infectious Diseases; 10/1/2001, Vol. 33 Issue 7, pe57
There is no recognized oral treatment for American cutaneous leishmaniasis. A rising-dose, open-label phase I/II trial of the oral agent miltefosine against Colombian cutaneous leishmaniasis was conducted. Seventy-two male Colombian soldiers (mean weight, 67 kg) received miltefosine at 50--100...
- Cutaneous leishmaniasis.
Marsden, P.D. // BMJ: British Medical Journal (International Edition); 6/30/90, Vol. 300 Issue 6741, p1716
Focuses on the treatment of leishmaniasis in Europe. Symptomatology of the disease; Recommendation of pentavalent antimonial drugs for the treatment of the disease; Disease diagnosis.
- Combined Interleukin-12 and Topical Chemotherapy for Established Leishmaniasis Drastically Reduces Tissue Parasitism and Relapses in Susceptible Mice.
Fernandes, Ana Paula; Ferreira, Lucas A. M.; Castro, Gisele A.; Carvalho, Fernando A. A.; Tavares, Carlos Alberto P.; Santiago, Helton C.; Tafuri, Wagner Luiz; Gazzinelli, Ricardo T. // Journal of Infectious Diseases; 6/1/2001, Vol. 183 Issue 11, p1646
Presents information on a study which examined the effectiveness of paramomycin sulfate with recombinant interleukin-12 in treating Leishmaniasis. Details on leishmaniasis; Methodology; Results and discussion.
- Successful Treatment of Drug-Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator.
Arevalo, Iracema; Ward, Brian; Miller, Richard; Meng, Tze-Chiang; Najar, Enrique; Alvarez, Eugenia; Matlashewski, Greg; Llamos-Cuentas, Alejandro // Clinical Infectious Diseases; 12/1/2001, Vol. 33 Issue 11, p2847
Treatment failures for leishmaniasis with pentavalent antimonials, including meglumine antimonate, are in-creasingly common in many endemic areas. Imiquimod (Aldara; 3M Pharmaceuticals) is a novel immune response--activating compound, approved by the United States Food and Drug Administration,...
- Variation of Proteinuria in Dogs with Leishmaniasis Treated with Meglumine Antimoniate and Allopurinol: A Retrospective Study.
Pierantozzi, Marco; Roura, Xavier; Paltrinieri, Saverio; Poggi, Marco; Zatelli, Andrea // Journal of the American Animal Hospital Association; Jul/Aug2013, Vol. 49 Issue 4, p231
The article discusses a study which determined how meglumine antimoniate and allopurinol treatments affect proteinuria levels in dogs diagnosed with leishmaniasis. Proteinuria for 53 dogs was evaluated through the urine protein/creatinine (UP/C) ratio. The experiment confirmed that after 4 to 8...
- Treatment failure may be result of Leishmania parasites' greater infectivity.
Oldt, Amanda; Shafer, Emily; Volansky, Rob // Infectious Disease News; Nov2013, Vol. 26 Issue 11, p18
The article discusses research being done on relapses after treatment for Leishmania infection, which references a study by K. Rai published in a 2013 issue of "mBio."
- Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and S-28436: Efficacy...
Buates, Sureemas; Matlashewski, Greg // Journal of Infectious Diseases; 6/1/99, Vol. 179 Issue 6, p1485
Studies the efficacy of the immunomodulators imiquimod and S-28463 in the treatment of experimental leishmaniasis. Measurement of nitric oxide (NO) production and inhibition of NO synthesis with N[sup G]-monomeethyl-L-arginine; Analysis of activated signal transducer and activator of...
- Leishmaniasis: will new technology provide a breakthrough?
Buates, Sureemas; Matlashewski, Greg // WHO Drug Information; 1999, Vol. 13 Issue 3, p150
Reports on developments concerning leishmaniasis treatment as of August 1999. Drug treatment; Vaccine development; World Health Organization's research on the analysis and mapping of genomes of five tropical parasites; Underestimation of the prevalence and impact of leishmaniasis.
- Comparetaive Study on Glucantime and Oral Terbinafine along with Systemic Glucantime on Cutaneous Leishmaniasis.
Ebrahimian, Saba; Asilian, Ali; Faghihi, Gita // Journal of Isfahan Medical School; 2/14/2011, Vol. 28 Issue 118, p1
Background: Cutaneous leishmaniasis is the endemic type of leishmaniasis in Iran especially Isfahan province. Pentavalent antimonials are the first line treatment in all kind of leismaniasis; but their high cost side effect and also injection from, shows the necessity of finding new ways of...
- Infectious disease: Combating visceral leishmaniasis.
Harrison, Charlotte // Nature Reviews Drug Discovery; Nov2013, Vol. 12 Issue 11, p828
The article discusses a research on the treatment of visceral leishmaniasis which references the study "Vaccination with Leishmania hemoglobin receptor-encoding DNA protects against visceral leishmanias," by R. Guha and colleagues in the 2013 issue of "Science Translational Medicine"
- Leishmaniasis treatmentâ€”a challenge that remains: a review.
Dilvani Santos; Carlos Coutinho; Maria Madeira; Carolina Bottino; Rodrigo Vieira; Samara Nascimento; Alice Bernardino; Saulo Bourguignon; Suzana Corte-Real; Rosa Pinho; Carlos Rodrigues; Helena Castro // Parasitology Research; Jun2008, Vol. 103 Issue 1, p1
AbstractÂ Â Leishmaniasis is a disease caused by flagellate protozoan Leishmania spp. and represents an emergent illness with high morbidity and mortality in the tropics and subtropics. Since the discovery of the first drugs for Leishmaniasis treatment (i.e., pentavalent antimonials), until...
- AstraZeneca and DNDi to collaborate on drug screening for neglected tropical diseases.
Dilvani Santos; Carlos Coutinho; Maria Madeira; Carolina Bottino; Rodrigo Vieira; Samara Nascimento; Alice Bernardino; Saulo Bourguignon; Suzana Corte-Real; Rosa Pinho; Carlos Rodrigues; Helena Castro // Biomedical Market Newsletter; 4/14/2012, Vol. 21, p1
The article informs that AstraZeneca PLC and the organization Drugs for Neglected Diseases initiative (DNDi) have announced to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness.
- New therapy for visceral leishmaniasis.
Dilvani Santos; Carlos Coutinho; Maria Madeira; Carolina Bottino; Rodrigo Vieira; Samara Nascimento; Alice Bernardino; Saulo Bourguignon; Suzana Corte-Real; Rosa Pinho; Carlos Rodrigues; Helena Castro // Weekly Epidemiological Record; 6/21/2002, Vol. 77 Issue 25, p210
Reports on the use of miltefosine, manufactured by German pharmaceutical company Zentaris, as a chemotherapeutic agent for oral administration against the parasitic disease leishmaniasis. Transmission of leishmaniasis through the bite of the sandfly; Clinical trials conforming to international...
- Visceral leishmaniasis in Afghanistan.
Leslie, Toby; Saleheen, Sarah; Sami, Mohammad; Mayan, Ismail; Mahboob, Najibullah; Fiekert, Kathy; Lenglet, Annick; Ord, Rosalynn; Reithinger, Richard // CMAJ: Canadian Medical Association Journal; 8/1/2006, Vol. 175 Issue 3, p245
Presents information on visceral leishmaniasis in Afghanistan after the fall of the Taliban in 2002. Epidemiology; Information on various clinical management, such as pentavalent antimony therapy and therapeutic approaches that include miltefosine; Strategies to prevent and control visceral...
Bryceson, Anthony; Lawson, Nigel; Taylor, Andrew; Fleiss, Paul M.; Fisher, R.F.; Sawyer, C.N.; Cleary, John; Gabriel, Roger; Baron, D.N.; Hoskins, Percy; Jackson, Doris; Hastings, Adrian; Redstone, I. // British Medical Journal (Clinical Research Edition); 11/19/1983, Vol. 287 Issue 6404, p1555
Presents the views of several physicians on medical issues in Great Britain. Effectivity of curettage in the treatment of cutaneous leishmaniasis; Correlation of serum parathyroid hormone measurements and hyperparathyroidism diagnosis; Information on toxic properties of the drug zimelidine.
- Antileishmanial Patents Antileishmanial Current Drugs and Relevant Patents.
Monzote, Lianet // Recent Patents on Anti-Infective Drug Discovery; Jan2011, Vol. 6 Issue 1, p1
The World Health Organization has classified the leishmaniasis as a major tropical disease. An effective vaccine is not available and the chemotherapy is the only effective way to treat all forms of disease. Currently, the therapy is toxic, expensive and the resistance has emerged as a serious...
Krause, G�rard; Kroeger, Axel; Soto, J.; Berman, J.; Pillay, Thillagavathie; Adhikari, Miriam; Lee, Lucia H.; Graman, Paul S.; Michaels, Stephanie H.; Clark, Rebecca; Kissinger, Patricia // Clinical Infectious Diseases; 8/1/1999, Vol. 29 Issue 2, p466
Presents several letters regarding infectious diseases. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis; Congenital tuberculosis in a neonatal intensive care unit; Incidence and spectrum of AIDS-defining...
- Inhibition of Leishmania major PTR1 Gene Expression by Antisense in Escherichia coli.
Kheirandish, F.; Bandehpour, M.; Haghighi, A.; Mahboudi, F.; Mohebali, M.; Kazemi, B. // Iranian Journal of Public Health; 2012, Vol. 41 Issue 6, p65
Background: Protozoa related to Trypanosome family including Leishmania, synthesize enzymes to escape from drug therapy. One of them is PTR1 that its enzymatic activity is similar to dihydrofolate reductase (DHFR). Dihydrofolate reductase--thymidylate synthase has a major role in DNA synthesis,...
- A Novel Organotellurium Compound (RT-01) as a New Antileishmanial Agent.
Cantalupo Lima, Camila Bárbera; Arrais-Silva, Wagner Welber; Rodrigues Cunha, Rodrigo Luiz Oliveira; Giorgio, Selma // Korean Journal of Parasitology; Sep2009, Vol. 47 Issue 3, p213
Leishmaniasis is a neglected disease and endemic in developing countries. A lack of adequate and definitive chemotherapeutic agents to fight against this infection has led to the investigation of numerous compounds. The aim of this study was to investigate the effect of RT-01, an organotellurane...
Cantalupo Lima, Camila Bárbera; Arrais-Silva, Wagner Welber; Rodrigues Cunha, Rodrigo Luiz Oliveira; Giorgio, Selma // WHO Technical Report Series; 2005, Issue 933, p35
The article reports on the submission of an application for the inclusion of miltefosine in the World Health Organization's Model List of Essential Medicines for treatment of leishmaniasis. The Committee has rejected the application, noting that any future application should include data...
- Use of meglumine antimoniate in canine leishmaniasis.
Lamothe, Jacques // Veterinary Record: Journal of the British Veterinary Association; 3/20/2004, Vol. 154 Issue 12, p378
Presents a letter to the editor about the use of meglumine antimoniate in canine leishmaniasis.
- Leishmania donovani Develops Resistance to Drug Combinations
García-Hernández, Raquel; Manzano, José Ignacio; Castanys, Santiago; Gamarro, Francisco // PLoS Neglected Tropical Diseases; Dec2012, Vol. 6 Issue 12, p1
Drug combinations for the treatment of leishmaniasis represent a promising and challenging chemotherapeutic strategy that has recently been implemented in different endemic areas. However, the vast majority of studies undertaken to date have ignored the potential risk that Leishmania parasites...
- Leishmania amazonensis Growth Inhibitors: Biological and Theoretical Features of Sulfonamide 4-Methoxychalcone Derivatives.
Souza, Alessandra M. T.; Castro, Helena C.; Brito, Monique A.; Andrighetti-Fröhner, Carla R.; Magalhães, Uiaran; Oliveira, Kely N.; Gaspar-Silva, Daniela; Pacheco, Letícia; Joussef, Antônio C.; Steindel, Mário; Simões, Cláudia M. O.; Santos, Dilvani O.; Albuquerque, Magaly G.; Rodrigues, Carlos R.; Nunes, Ricardo J. // Current Microbiology; Oct2009, Vol. 59 Issue 4, p374
Current drugs for treating leishmaniasis are still associated with significant toxicity and failure rates. Thus, new effective and less toxic antileishmanial agents are still in need. Herein, we tested a series of sulfonamide 4-methoxychalcone derivatives against L. amazonensis promastigote and...
- Liposomal Amphotericin B in the Treatment of Fungal Infections.
Lopez-Berestein, Gabriel // Annals of Internal Medicine; Jul86, Vol. 105 Issue 1, p130
Editorial. Discusses the use of amphotericin B, a polyene antibiotic, in the treatment of systemic fungal infections. Effectiveness of the agent for the treatment of leishmaniasis; Mechanism of action of amphotericin B; Definition of the term liposomes; Therapeutic use of liposomal amphotericin B.
- Evaluation of Leishmanicidal Activity of Oxypeucedanin and Isoimperatorin on Leishmania major Promastigotes.
Sajjadi, Seyed Ebrahim; Eskandarian, Abbas-Ali; Yousefi, Hossein-Ali; Mansourian, Marjan; Taheri, Mohammad // Journal of Isfahan Medical School; Jul2013, Vol. 31 Issue 235, p581
Background: Leishmaniasis has a wide range of clinical symptoms including cutaneous, mucocutaneous, and visceral leishmaniasis. Recently, advances have been observed in the field of using herbal medicines for the treatment of leishmaniasis. The study aimed to determine the in-vitro effect of two...
- Antileishmanial Agents: An Updated Review.
Pathak, Devender; Yadav, Mithlesh; Siddiqui, Nadeem; Kushawah, Sapana // Der Pharma Chemica; 2011, Vol. 3 Issue 1, p239
Antileishmanial activity is associated with diverse heterocyclic nucleus such as piperazine, pyrimidine, quinoline, azoles (imidazole, 1, 2, 4 triazole, isoxazole, pyrazole, thiazole, thiadiazole), quinazoline, acridine and indole. This review article covers different heterocyclic nucleus with...
- Nonhealing but painless cheek ulcer.
Sonabend, Michael // Clinical Advisor for Nurse Practitioners; Nov2010, Vol. 13 Issue 11, p93
The article presents a case study of a Hispanic man age 23 years with nine-month history of a nonhealing ulcer of his cheek. He was diagnosed with parasitic disease, New World Leishmaniasis, caused by protozoan of the genus Lutzomyia from sandflies' bites. The article discusses the treatment...
- Cheminformatic models based on machine learning for pyruvate kinase inhibitors of Leishmania mexicana.
Jamal, Salma; Scaria, Vinod // BMC Bioinformatics; 2013, Vol. 14 Issue 1, p1
Background Leishmaniasis is a neglected tropical disease which affects approx. 12 million individuals worldwide and caused by parasite Leishmania. The current drugs used in the treatment of Leishmaniasis are highly toxic and has seen widespread emergence of drug resistant strains which...
- Control of visceral leishmaniasis in Brazil:recommendations from Brasileish.
Ribeiro, Vitor Márcio; da Silva, Sydnei Magno; Menz, Ingrid; Tabanez, Paulo; Santos Nogueira, Fábio dos; Werkhaüser, Manfredo; da Fonseca, André Luis S.; Dantas-Torres, Filipe // Parasites & Vectors; 2013, Vol. 6 Issue 1, p1
On 26 October 2012, veterinary medicine clinicians and researchers, members of Brasileish - Study Group about Animal Leishmaniasis - met at the Regional Council of Veterinary Medicine of Minas Gerais, in the city Belo Horizonte, in order to discuss many aspects of the situation of canine...
- PENTAMIDINE MESILATE.
Ribeiro, Vitor Márcio; da Silva, Sydnei Magno; Menz, Ingrid; Tabanez, Paulo; Santos Nogueira, Fábio dos; Werkhaüser, Manfredo; da Fonseca, André Luis S.; Dantas-Torres, Filipe // International Pharmacopoeia: Fourth Edition; 2006, Vol. 2, p725
A monograph for the pharmaceutical substance "PENTAMIDINI MESILAS/PENTAMIDINE MESILATE" from the fourth edition of "The International Pharmacopoeia" is presented. Pentamidine mesilate is categorized as antitrypanosomal drug or antileishmaniansis drug, and described as an almost odourless, whit...
- Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Danilo C. Miguel; Rogéria C. Zauli-Nascimento; Jenicer K. U. Yokoyama-Yasunaka; Simone Katz; Clara L. Barbiéri; Silvia R. B. Uliana // Journal of Antimicrobial Chemotherapy (JAC); Feb2009, Vol. 63 Issue 2, p365
: Objectives The aim of this study was to evaluate the efficacy of tamoxifen in vivo in experimental models of cutaneous (CL) and visceral leishmaniasis (VL) caused by Leishmania braziliensis and Leishmania chagasi, respectively. : Methods Drug activity was assessed against intracellular...
- Induction of Apoptosis by Miltefosine in Iranian Strain Leishmania infantum Promastigotes.
Khademvatan, S.; Gharavi, M. J.; Akhlaghi, L.; Samadikuchaksaraei, A.; Oormazdi, H.; Mousavizadeh, K.; Hadighi, R.; Saki, J. // Iranian Journal of Parasitology; 2009, Vol. 4 Issue 2, p23
Background: Miltefosine is a new drug of choice for the treatment of visceral leishmaniasis. Numerous experimental studies have shown miltefosine is effective on Leishmania donovani, however, effectiveness of miltefosine in treatment of L. infantum is not fully understood. The aims of the...
- Immune Regulation during Chronic Visceral Leishmaniasis.
Faleiro, Rebecca J.; Kumar, Rajiv; Hafner, Louise M.; Engwerda, Christian R. // PLoS Neglected Tropical Diseases; Jul2014, Vol. 8 Issue 7, p1
Visceral leishmaniasis is a chronic parasitic disease associated with severe immune dysfunction. Treatment options are limited to relatively toxic drugs, and there is no vaccine for humans available. Hence, there is an urgent need to better understand immune responses following infection with...
- Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Sanderson, Lisa; Yardley, Vanessa; Croft, Simon L. // Journal of Antimicrobial Chemotherapy (JAC); Jul2014, Vol. 69 Issue 7, p1888
Objectives There is an urgent need to develop new and effective treatments for poverty-related neglected diseases. In light of the time required to bring a new drug to market and the cost involved (10â€“15 years, >1 billion US$), one approach to identifying new treatments for diseases like...
- U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis.
Meyerhoff, Andera // Clinical Infectious Diseases; 1/1/1999, Vol. 28 Issue 1, p42
Reports on the United States Food and Drug Administration's approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Access to drugs for the treatment of the infection; Use of historical control and data studies for the approval of the drug.
- Editorial Response: U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis.
Berman, Jonathan D. // Clinical Infectious Diseases; 1/1/1999, Vol. 28 Issue 1, p49
Focuses on the United States Food and Drug Administration's approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Standard treatment of visceral leishmaniasis; Pros and cons of amphotericin B therapy.
- A Randomized, Double-Blind Study of the Efficacy of a 10- or 20-Day Course of Sodium Stibogluconate for Treatment of Cutaneous Leishmaniasis in United States Military Personnel.
Wortmann, Glenn; Miller, R. Scott; Oster, Charles; Jackson, Joan; Aronson, Naomi // Clinical Infectious Diseases; 8/1/2002, Vol. 35 Issue 3, p261
The recommended treatment for cutaneous leishmaniasis is pentavalent antimony at a dosage of 20 mg/kg/ day for 20 days. Some studies conducted in locales in which Leishmania is endemic have suggested that shorter courses of treatment may be as efficacious. We conducted a randomized,...
- Topical Fluconazole Combined with Local Glucantime Injection Compared with Local Glucantime Injections in Treatment of Leishmaniasis.
Nilforooshzadeh, Mohammad Ali; Hejazi, Seyed Hossein; Nabipour, Reza // Journal of Isfahan Medical School; 2/14/2011, Vol. 28 Issue 118, p1
Background: Leishmaniasis is one of the 6th important infectious diseases in the world that has been certificated as an endemic disease in Iran. The aim of this study was comparison of two methods of treatment included flouconazole with glucantime and glucantime alone in treatment of...
- Amplified Fragment Length Polymorphisms Reveals High Intraspecific Variability in Field Isolates of Leishmania panamensis.
Restrepo, Carlos M.; Lao, Efraín Pérez; De La Guardia, Carolina; Sousa, Octavio E.; Calzada, José E.; Lleonart, Ricardo // Current Trends in Biotechnology & Pharmacy; Apr2011, Vol. 5 Issue 2, p1183
Leishmania parasites cause leishmaniasis, a potentially deadly re-emergent disease that affects millions throughout the world. In Panama, the disease is showing an increasing trend, with estimates of thousands of new cases every year. The main manifestations are the cutaneous and mucocutaneous...